GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » 14-Day RSI

Arecor Therapeutics (LSE:AREC) 14-Day RSI : 66.80 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-21), Arecor Therapeutics's 14-Day RSI is 66.80.

The industry rank for Arecor Therapeutics's 14-Day RSI or its related term are showing as below:

LSE:AREC's 14-Day RSI is ranked worse than
92.24% of 1572 companies
in the Biotechnology industry
Industry Median: 48.52 vs LSE:AREC: 66.80

Competitive Comparison of Arecor Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Arecor Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arecor Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's 14-Day RSI falls into.



Arecor Therapeutics  (LSE:AREC) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arecor Therapeutics  (LSE:AREC) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Arecor Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Arecor Therapeutics (LSE:AREC) Business Description

Traded in Other Exchanges
Address
Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.

Arecor Therapeutics (LSE:AREC) Headlines

From GuruFocus